# Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

> **NCT01177540** · PHASE2 · TERMINATED · sponsor: **Eisai Inc.** · enrollment: 25 (actual)

## Conditions studied

- Pediatric Acute Myelogenous Leukemia (AML)

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT01177540
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-03-03
- **Primary completion:** 2013-07-19
- **Final completion:** 2013-07-19
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** The study was terminated early due to enrollment difficulties and the futility of observing differences in remission rate between treatment arms.
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01177540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01177540, "Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01177540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*